William Symmans, MD
Cytopathology · Houston, TXNPI 1669577367
Payments from drug & device makers
What this record shows
4 manufacturers reported payments, led by Astrazeneca UK Limited at 40.7% of the total. Among cytopathology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 8 payments — averaging $1120.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$4K
- F. Hoffmann-la Roche AG$3K
- Merck$1K
- Pfizer$620
Across 14 payments — averaging $4100.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$57K
- F. Hoffmann-la Roche AG$842
What the payments were for
- Consulting fees$4,92555%
- Speaking & faculty fees$4,04245%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 3 | $3,650 |
| F. Hoffmann-la Roche AG | 3 | $3,422 |
| Merck | 1 | $1,275 |
| Pfizer | 1 | $620 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,967 in reported general payments places this provider in the 90th percentile of 24 cytopathology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cytopathology in Houston
- Neda KalhorHouston$30K
- Kidada Gilbert-LewisHouston$828
- Linda GreenHouston$223
- Ming GuoHouston$176
- Yun GongHouston$86
- Xiao HuangHouston$86
- Christina FanningHouston$72
- John StewartHouston$39
- Gordana VerstovsekHouston$14
- Luis de Las CasasDallas$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.